--- title: "Steel Partners 将目标锁定 InMode，理由是其股票表现不佳" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/274188009.md" description: "Steel Partners Holdings 提出了一个未经请求的收购提议，计划以每股 18 美元收购 InMode Ltd. (INMD) 的控股权，溢价 29%。该公司批评了 InMode 的股票表现、资本配置和业绩指引下调，指出其总股东回报为负。Steel Partners 持有 InMode 1.3% 的股份，并声称其提议反映了该公司的业绩不佳和现金管理问题。该提议完全通过现有现金和借款能力进行融资。在消息公布后，InMode 的股票上涨了 5.82%，达到 16 美元" datetime: "2026-01-29T17:44:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274188009.md) - [en](https://longbridge.com/en/news/274188009.md) - [zh-HK](https://longbridge.com/zh-HK/news/274188009.md) --- # Steel Partners 将目标锁定 InMode，理由是其股票表现不佳 **Steel Partners Holdings** on Wednesday publicly disclosed an unsolicited proposal to acquire a controlling stake in **InMode Ltd. ( INMD )** , offering shareholders a cash premium while criticizing the company's stock performance, capital allocation, and repeated guidance cuts. The stock is trading near the upper end of its 52-week range of $13.14-19.78, according to Benzinga Pro data. Steel Partners approached InMode ( INMD ) about acquiring 51% of the company's outstanding shares at $18 per share. The offer represents a 29% premium to InMode's ( INMD ) January 23 closing price, before media speculation surrounding a possible transaction emerged. Steel Partners is already a shareholder, with roughly 800,000 InMode ( INMD ) shares. That’s about 1.3% of the company. According to the letter, Steel Partners has made numerous efforts to engage privately regarding the proposal but was rebuffed. Steel Partners stated that its valuation reflects its assessment of InMode's ( INMD ) business and growth outlook. The proposal would be funded entirely through existing cash and available borrowing capacity, with no financing contingencies, the firm said. The letter highlighted what Steel Partners described as InMode's ( INMD ) prolonged underperformance. Total shareholder return stood at negative 19.18% over the past year, negative 59.35% over three years, and negative 53.24% over five years, according to figures cited in the letter. Steel Partners also criticized InMode's ( INMD ) balance sheet strategy, noting the company held $532.3 million in cash and cash equivalents as of its third-quarter 2025 earnings report, nearly half of its market capitalization, while carrying no debt. The firm argued that InMode ( INMD ) has failed to return excess cash to shareholders in a consistent and value-enhancing manner. In addition, Steel Partners pointed to InMode's ( INMD ) history of lowering guidance, citing seven reductions over the past nine quarters and additional downward revisions to the top end of 2025 revenue and non-GAAP gross margin guidance earlier this month. InMode Sees preliminary fourth quarter sales of $103.60 million-$103.80 million compared to the consensus of $104.44 million. The medical technology company narrowed fiscal 2025 sales from $365-$375 million to $370.2-$370.4 million versus the consensus of $370.55 million. InMode ( INMD ) forecasts fiscal 2026 sales of $365-$375 million compared to the Wall Street estimate of $384.47 million. Steel Partners said it remains willing to engage with InMode's ( INMD ) leadership and may pursue a binding offer directly with shareholders if discussions do not move forward. **Price Action**: INMD stock is up 5.82% at $16 at the last check on Thursday, according to Benzinga Pro data. _Image: Shutterstock_ ### 相关股票 - [INMD.US](https://longbridge.com/zh-CN/quote/INMD.US.md) - [SPLP.US](https://longbridge.com/zh-CN/quote/SPLP.US.md) - [XHE.US](https://longbridge.com/zh-CN/quote/XHE.US.md) - [IHI.US](https://longbridge.com/zh-CN/quote/IHI.US.md) ## 相关资讯与研究 - [强生公司销售额增长近 10%，上调 2026 年业绩展望](https://longbridge.com/zh-CN/news/282850988.md) - [杰富瑞对 InMode (INMD) 维持持有评级](https://longbridge.com/zh-CN/news/282695859.md) - [Science Corporation 拟启动生物混合脑机接口人体试验](https://longbridge.com/zh-CN/news/282927372.md) - [InMode 在 Needham 会议上表示，美容需求放缓，Picofy 推动了第一季度的增长，同时面临利润率压力](https://longbridge.com/zh-CN/news/282651250.md) - [理解市场 | 再鼎医药涨超 4% 宣布与勃林格殷格翰合作开发创新双 DLL3 靶向药物联合疗法](https://longbridge.com/zh-CN/news/282924756.md)